Tratamiento de alta intensidad con estatinas para pacientes estables en monoterapia con ácido acetilsalicílico a los 12 meses de un implante de stent farmacoactivo: estudio aleatorizado

Eui Im; Yun Hyeong Cho; Yongsung Suh; Deok Kyu Cho; Ae Young Her; Yong Hoon Kim; Kyounghoon Lee; Woong Chol Kang; Kyeong Ho Yun; Sang Yong Yoo; Sang Sig Cheong; Dong Ho Shin; Chul Min Ahn; Jung Sun Kim; Byeong Keuk Kim; Young Guk Ko; Donghoon Choi; Yangsoo Jang; Myeong Ki Hong

doi:10.1016/j.recesp.2017.05.028

Tratamiento de alta intensidad con estatinas para pacientes estables en monoterapia con ácido acetilsalicílico a los 12 meses de un implante de stent farmacoactivo: estudio aleatorizado

Translated title of the contribution: High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study

Eui Im, Yun Hyeong Cho, Yongsung Suh, Deok Kyu Cho, Ae Young Her, Yong Hoon Kim, Kyounghoon Lee, Woong Chol Kang, Kyeong Ho Yun, Sang Yong Yoo, Sang Sig Cheong, Dong Ho Shin, Chul Min Ahn, Jung Sun Kim, Byeong Keuk Kim, Young Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong Ki Hong

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Introduction and objectives: Current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (DES)-treated patients. However, high-intensity statin treatment is frequently underused in clinical practice after stabilization of DES-treated patients. Currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. We investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after DES implantation. Methods: Clinically stable patients who underwent DES implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40 mg atorvastatin, n = 1000) or low-intensity (20 mg pravastatin, n = 1000) statin treatment. The primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events). Results: The primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving high-intensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (HR, 0.58; 95%CI, 0.36-0.92; P =.018). This difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, P =.025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, P =.033) in the high-intensity statin treatment group. Conclusions: Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075. Full English text available from: www.revespcardiol.org/en

Translated title of the contribution	High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
Original language	Spanish
Pages (from-to)	423-431
Number of pages	9
Journal	Revista Espanola de Cardiologia
Volume	71
Issue number	6
DOIs	https://doi.org/10.1016/j.recesp.2017.05.028
Publication status	Published - 2018 Jun

Bibliographical note

Funding Information:
Este estudio ha sido financiado con subvenciones del Korea Healthcare Technology Research & Development Project, Ministerio de Salud y Bienestar, República de Corea (números A085136 y H115C1277), el Mid-career Researcher Program a través de la National Research Foundation financiada por el Ministerio de Educación, Ciencia y Tecnología, República de Corea (número 2015R1A2A2A01002731), Yuhan Corporation, Corea, CJ HealthCare, Corea, Daiichi Sankyo Korea Co, Ltd. y el Cardiovascular Research Center, Seúl, Corea.

Publisher Copyright:
© 2017 Sociedad Española de Cardiología

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.recesp.2017.05.028

Cite this

Im, E., Cho, Y. H., Suh, Y., Cho, D. K., Her, A. Y., Kim, Y. H., Lee, K., Kang, W. C., Yun, K. H., Yoo, S. Y., Cheong, S. S., Shin, D. H., Ahn, C. M., Kim, J. S., Kim, B. K., Ko, Y. G., Choi, D., Jang, Y., & Hong, M. K. (2018). Tratamiento de alta intensidad con estatinas para pacientes estables en monoterapia con ácido acetilsalicílico a los 12 meses de un implante de stent farmacoactivo: estudio aleatorizado. Revista Espanola de Cardiologia, 71(6), 423-431. https://doi.org/10.1016/j.recesp.2017.05.028

@article{9220befa0ccc4936bf0687adefb2b39f,

title = "Tratamiento de alta intensidad con estatinas para pacientes estables en monoterapia con {\'a}cido acetilsalic{\'i}lico a los 12 meses de un implante de stent farmacoactivo: estudio aleatorizado",

abstract = "Introduction and objectives: Current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (DES)-treated patients. However, high-intensity statin treatment is frequently underused in clinical practice after stabilization of DES-treated patients. Currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. We investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after DES implantation. Methods: Clinically stable patients who underwent DES implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40 mg atorvastatin, n = 1000) or low-intensity (20 mg pravastatin, n = 1000) statin treatment. The primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events). Results: The primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving high-intensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (HR, 0.58; 95%CI, 0.36-0.92; P =.018). This difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, P =.025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, P =.033) in the high-intensity statin treatment group. Conclusions: Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075. Full English text available from: www.revespcardiol.org/en",

author = "Eui Im and Cho, {Yun Hyeong} and Yongsung Suh and Cho, {Deok Kyu} and Her, {Ae Young} and Kim, {Yong Hoon} and Kyounghoon Lee and Kang, {Woong Chol} and Yun, {Kyeong Ho} and Yoo, {Sang Yong} and Cheong, {Sang Sig} and Shin, {Dong Ho} and Ahn, {Chul Min} and Kim, {Jung Sun} and Kim, {Byeong Keuk} and Ko, {Young Guk} and Donghoon Choi and Yangsoo Jang and Hong, {Myeong Ki}",

note = "Publisher Copyright: {\textcopyright} 2017 Sociedad Espa{\~n}ola de Cardiolog{\'i}a",

year = "2018",

month = jun,

doi = "10.1016/j.recesp.2017.05.028",

language = "Spanish",

volume = "71",

pages = "423--431",

journal = "Revista Espanola de Cardiologia",

issn = "0300-8932",

publisher = "Ediciones Doyma, S.L.",

number = "6",

}

Im, E, Cho, YH, Suh, Y, Cho, DK, Her, AY, Kim, YH, Lee, K, Kang, WC, Yun, KH, Yoo, SY, Cheong, SS, Shin, DH, Ahn, CM, Kim, JS, Kim, BK, Ko, YG, Choi, D , Jang, Y & Hong, MK 2018, 'Tratamiento de alta intensidad con estatinas para pacientes estables en monoterapia con ácido acetilsalicílico a los 12 meses de un implante de stent farmacoactivo: estudio aleatorizado', Revista Espanola de Cardiologia, vol. 71, no. 6, pp. 423-431. https://doi.org/10.1016/j.recesp.2017.05.028

Tratamiento de alta intensidad con estatinas para pacientes estables en monoterapia con ácido acetilsalicílico a los 12 meses de un implante de stent farmacoactivo: estudio aleatorizado. / Im, Eui; Cho, Yun Hyeong; Suh, Yongsung et al.
In: Revista Espanola de Cardiologia, Vol. 71, No. 6, 06.2018, p. 423-431.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Tratamiento de alta intensidad con estatinas para pacientes estables en monoterapia con ácido acetilsalicílico a los 12 meses de un implante de stent farmacoactivo

T2 - estudio aleatorizado

AU - Im, Eui

AU - Cho, Yun Hyeong

AU - Suh, Yongsung

AU - Cho, Deok Kyu

AU - Her, Ae Young

AU - Kim, Yong Hoon

AU - Lee, Kyounghoon

AU - Kang, Woong Chol

AU - Yun, Kyeong Ho

AU - Yoo, Sang Yong

AU - Cheong, Sang Sig

AU - Shin, Dong Ho

AU - Ahn, Chul Min

AU - Kim, Jung Sun

AU - Kim, Byeong Keuk

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Hong, Myeong Ki

PY - 2018/6

Y1 - 2018/6

N2 - Introduction and objectives: Current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (DES)-treated patients. However, high-intensity statin treatment is frequently underused in clinical practice after stabilization of DES-treated patients. Currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. We investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after DES implantation. Methods: Clinically stable patients who underwent DES implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40 mg atorvastatin, n = 1000) or low-intensity (20 mg pravastatin, n = 1000) statin treatment. The primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events). Results: The primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving high-intensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (HR, 0.58; 95%CI, 0.36-0.92; P =.018). This difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, P =.025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, P =.033) in the high-intensity statin treatment group. Conclusions: Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075. Full English text available from: www.revespcardiol.org/en

AB - Introduction and objectives: Current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (DES)-treated patients. However, high-intensity statin treatment is frequently underused in clinical practice after stabilization of DES-treated patients. Currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. We investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after DES implantation. Methods: Clinically stable patients who underwent DES implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40 mg atorvastatin, n = 1000) or low-intensity (20 mg pravastatin, n = 1000) statin treatment. The primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events). Results: The primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving high-intensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (HR, 0.58; 95%CI, 0.36-0.92; P =.018). This difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, P =.025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, P =.033) in the high-intensity statin treatment group. Conclusions: Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075. Full English text available from: www.revespcardiol.org/en

UR - http://www.scopus.com/inward/record.url?scp=85031750780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031750780&partnerID=8YFLogxK

U2 - 10.1016/j.recesp.2017.05.028

DO - 10.1016/j.recesp.2017.05.028

M3 - Article

C2 - 28716428

AN - SCOPUS:85031750780

SN - 0300-8932

VL - 71

SP - 423

EP - 431

JO - Revista Espanola de Cardiologia

JF - Revista Espanola de Cardiologia

IS - 6

ER -

Tratamiento de alta intensidad con estatinas para pacientes estables en monoterapia con ácido acetilsalicílico a los 12 meses de un implante de stent farmacoactivo: estudio aleatorizado

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this